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Background: Recently, exchanging data and information has become a significant challenge in medicine. Such
data include abnormal states. Establishing a unified representation framework of abnormal states can be a difficult
task because of the diverse and heterogeneous nature of these states. Furthermore, in the definition of diseases
found in several textbooks or dictionaries, abnormal states are not directly associated with the corresponding
quantitative values of clinical test data, making the processing of such data by computers difficult.
Results: We focused on abnormal states in the definition of diseases and proposed a unified form to describe an
abnormal state as a “property,” which can be decomposed into an “attribute” and a “value” in a qualitative representation.
We have developed a three-layer ontological model of abnormal states from the generic to disease-specific level. By
developing an is-a hierarchy and combining causal chains of diseases, 21,000 abnormal states from 6000 diseases have been
captured as generic causal relations and commonalities have been found among diseases across 13 medical departments.
Conclusions: Our results showed that our representation framework promotes interoperability and flexibility of the
quantitative raw data, qualitative information, and generic/conceptual knowledge of abnormal states. In addition, the
results showed that our ontological model have found commonalities in abnormal states among diseases across 13
medical departments.
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With the development of newer technologies, data and
information exchange have been required for several
applications such as electronic health records (EHR) in
medicine. Such data and information include abnormal
states. However, abnormal states are difficult to share
because of their heterogeneity, caused by the variety of
grain sizes, from the level of cells, tissue, and organs to
that of the entire human body. This results in diverse
representations with little uniformity. BFO [1,2] and
DOLCE [3] have contributed to the formalization of the
quality description of entities. BFO provides E (Entity),
P (Property) (e.g., <Eye (E), red (P)>) and DOLCE provides
E (Entity), A (Attribute), V (Value) triple (e.g., <esophagus
(E), length (A), short (V)>). However, we found that there
are more complicated forms of quality representations
in medicine. For example, “hypertension” is a compound* Correspondence: yamagata@ei.sanken.osaka-u.ac.jp
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unless otherwise stated.concept, which has three elements: blood, pressure, and
high joined to form one concept/word. Another example
is “hyperglycemia,” composed of four concepts: blood,
glucose, concentration, and high. Furthermore, in the case
of “intestinal polyposis,” it is unclear whether “intestine”
or “polyp” should be considered as the entity.
This motivated us to establish a common framework
for the representation of abnormal states supported by
sound theories. In this study, we investigate the repre-
sentation of abnormal states from the content-oriented
view, which focuses on how to capture the content to be
represented, on the basis YAMATO [4].
YAMATO has been built to target both high utility
and philosophical soundness while maintaining compati-
bility with BFO and DOLCE. In brief, YAMATO has the
following characteristics:
a) Quality-related concepts (dependent continuant
entities) are divided into “Property,” “Generic
quality,” and “Quality value.” “Quality” in BFO is
identical to “Property” in YAMATO.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the classification in scales of measurement.
c) The context dependency of “Ordinal value” is
represented by using the theory of “Role”.
d) Multiple kinds of informational entities are
symbolically represented.
For the quality description, representations with
both EAV and EP formalisms are defined. Furthermore,
PATO2YAMATO aims to integrate phenotype >descriptions
that exist in different structured comparison contexts [5].
It allows (1) the classification of quality values, in which
scales of measurements are properly represented; (2) strict
modeling of the context dependency of ordinal values;
and (3) clear distinction between “true values” and “mea-
sured data.” It provides the mapping of ontology terms
of PATO [6] to YAMATO’s framework and enables
the interoperability of the quality framework between
different top-level ontologies such as BFO and DOLCE. For
example, in the YAMATO framework, PATO:0000582
(increased weight) is defined as a Property that is a com-
bination of Generic quality (Attribute), weight, and a
context-dependent Quality value (Attribute Value), heavy.
The context-independent value is defined as a class
“Weight quality value.”
Another issue is that in several medical textbooks or
medical dictionaries, abnormal states in the definitions
of diseases have not been directly associated with the
corresponding quantitative values of clinical test data (e.g.,
“ischemia” in ischemic heart disease or “muscular weak-
ness” in muscular dystrophy), which makes their processing
by a computer difficult.
Furthermore, clinicians often deal with abnormal states
specific to each disease only in a particular medical division,
which makes it difficult to spread awareness regarding
the common nature of abnormal states. To address these
issues, we have been developing abnormality ontology for
the systematization of knowledge regarding abnormal
states, using ontological engineering, which represents a
unified framework [7]. We focus on abnormal states in
the definitions of diseases, which should be referred to
in several applications. In addition, we discuss the rep-
resentation of the various abnormal states on the basis
of ontological theories in a consistent manner.
Our claim in this study is not isolated to adopting one
of the representational forms used in the existing re-
sources. The aim of our work is to formalize and organize
different representations used in clinical medicine on the
basis of ontological theories, and to realize the interoper-
ability between them. It's not a simple matter of the use of
existing resources such as PATO, LOINC [8], and others.
Unified theoretical considerations make the various repre-
sentation forms interoperable, which enables the establish-
ment of a consistent and computer understandable modelfor abnormal states that are used in the definitions of
diseases and medical data.
In this study, we first define abnormal states and
explain our representation model. Then, we introduce our
ontology of abnormal states and demonstrate an applica-
tion of our work. We have constructed a disease ontology
and captured a disease as one or more causal chains of
the abnormal states in the human body [9]. Till date, clini-
cians have described the causal chains of approximately
21,000 abnormal states for approximately 6,000 diseases
across 13 medical departments. Thus, we believe that the
use of our ontology will contribute to various clinical
applications.
Results
Definition of abnormal states
In the human body, abnormal states are highly diverse
and involve various grain sizes, from the level of cells,
tissue, and organs to that of the whole organism. There-
fore, to systematize the knowledge about abnormal states,
it is important to clarify the essential characteristics of the
abnormal states, and to conceptualize them in a consistent
manner.
In this section, we focus on the abnormal states that
appear in the definition of diseases rather than in reality.
A “state” is modeled as a time-indexed propertya that is
associated with an entity, and has the value of an attri-
bute that changes with time [10]. For example, imagine
the state of hunger. It is represented by “being hungry”
or not at some time point in time. We define “Property”
as a characteristic that is inherent in an entity, having an
attribute along with its value, such as “being red”: <color,
red>. Properties are distinct from attribute values; for ex-
ample, the Property “hypertension” is differentiated from
an Attribute Value such as “high” as in “blood pressure is
high.” An Attribute Value has three subclasses: categorical
value (e.g., viviparous/oviparous), quantitative value (e.g.,
160 mmHg), and qualitative value (e.g., high/low, large/
small, much/few). On one hand, the Attribute Value “high”
can be used for several attributes such as temperature,
density, and velocity. On the other hand, the Property
“hypertension” cannot be used for the values of the above-
mentioned attributes and it has a set of attributes and
values like < pressure, high >.
In several textbooks and dictionaries, diseases have
been defined in terms of abnormal states. For example,
the definition of diabetes is “Diabetes mellitus is charac-
terized by chronic hyperglycemia with disturbances of…”
[11]. Another disease myocardial ischemia is presented
as “The term acute myocardial infarction should be used
when there is evidence of myocardial necrosis with acute
myocardial ischemia” [12]. Therefore, we can say that a
disease can be defined in terms of an assertion about the
patient “being in an abnormal state or not”.
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tions for abnormal states are used, and we conceptualize
these representations into three categories:
(1) Quantitative representation (e.g., blood pressure is
180 mmHg, blood glucose concentration is
135 mg/dL).
(2) Qualitative representation (e.g., blood pressure is
high, blood glucose concentration is high).
(3) Property representation (e.g., hypertension,
hyperglycemia).
Because the upper ontology YAMATO [4] has been care-
fully designed to cover the property, quality, and quantity
ontologies, it supports our work on abnormal states.
A quantitative representation is important for diagnosis
because a concrete value should be identified by clinical
examination for each patient. However, in the definition
of a disease, a property such as “being hypertensive” or
“being hyperglycemic” is essential instead of quantitative
data. Thus, as our basic policy, we first capture the
abnormal states as properties, represented by a tuple
like < Property (P), Property Value (Vp)>. The Property
Value takes a binary value, i.e., <true/false>. For example,
if the state “stenosis” exists, it is described as < stenosis,
true>. In addition, when necessary, a Degree Value (Vd)
can be used for describing the degree of the Property
Value, such as < stenosis, severe >.
Some readers may think that a property represented in
the above manner is extremely conceptual to be of prac-
tical use because of the lack of a representation, which
would give a more concrete meaning to data. Therefore,
we specify a property by decomposing it into a tuple: <At-
tribute (A), Attribute Value (V)>. The Attribute Value
can be either a Qualitative Value (Vql) or a Quantita-
tive Value (Vqt). For example, in a case of a qualitative
representation, stenosis (P) is decomposed into < cross
sectional area (A), small (Vql)>, and in another case of
a quantitative representation, stenosis (P) is described
as a concrete value, e.g., <cross sectional area (A),
5 mm2 (Vql)>. This approach contributes to promoting
consistency in representation, as well as the interoper-
ability between the quantitative raw data and the
generic/conceptual knowledge regarding abnormal states
(see after the section Interoperability between properties
and attributes).
In clinical medicine, decomposition of some prop-
erties cannot be achieved, because the precise mech-
anisms in the human body have not yet been completely
uncovered. For example, in the case of nausea, property
representation could be nondecomposable. Whether such
abnormal states represented in terms of properties defined
above can be decomposed into a known attribute and its
value will depend on advances in medicine.Representation of abnormal states
Basic representation
In this section, we introduce our representation model
for clinical abnormal states and show that we can appro-
priately represent them in a consistent manner.
Because an attribute cannot exist by itself but always
exists in association with an independent object, we need
to identify the object (hereinafter referred to as “target
object”). For example, in the case of “gastrectasia,” the
target object of its attribute “volume” is the stomach.
Accordingly, we introduce the “Object” to represent the
target object of the attribute and decompose the prop-
erty into a triple: <Object (O), Attribute (A), Attribute
Value (V)>. This is our basic representation model for
abnormalities. For example, “gastrectasia” is decomposed
into < stomach, volume, large > b (Table 1(a), row 1).
Extended representation
We recognize that some properties may be difficult to
decompose into the basic triple representation, such as a
ratio and what we call a meta-attribute, discussed below.
Accordingly, we introduce a “Sub-object” (SO) to repre-
sent a focused object (see next paragraph) as an extended
representation, so that a property can be decomposed into
a quadruple: <Object (O), Sub-Object (SO), Attribute (A),
Attribute Value (V) >.
In the case of a ratio, in addition to identifying the
target object with the ratio, it should represent for what
will be focused on (“focused object”). Therefore, we
introduce a Sub-Object (SO) to represent a focused ob-
ject. For example, the representation of “hyperglycemia” is
a quadruple, <blood (O), glucose (SO), concentration (A),
high (V)>, where the Object is blood and the Sub-Object
is glucose [Table 1(a), row 3].
There appear to be different kinds of ratios depending
on what is focused on. As a result, the Object and Sub-
Object vary according to the type of ratio. Our representa-
tion model can represent all of them, as shown in Table 1
(b). A detailed discussion can be found in a report by
Yamagata Y et al. [13].
Furthermore, we show the representation of a meta-
attribute. In the case of the property “gastric polyposis,”
although color and size are attributes of polyps, “many
polyps” is not an attribute of “polyps” because it is not
inherent in each polyp. Following the meta-attribute
approach in YAMATO, where, in the case of “the road
is curvy,” “number of curves” is identified as a meta-
attribute of curves, and the road, which has many
curves, can be represented in terms of it (the number
curves). Accordingly, we regard “the number of polyps”
as a meta-attribute of polyps and the stomach can be
described in the same manner as a road. By introducing
“Sub-object,” the property “gastric polyposis” can be
decomposed into a quadruple < stomach (O), polyps (SO),
Table 1 Representations of abnormal states
(a) Representation Abnormal statesProperty (P)
Property
Value (Vp) Attribute (A)
Attribute
Value (V) Object (O) Sub-Object (SO)
Basic representation
Gasrtectasia (gastric dilation) True Volume Large Stomach
Nausea True Patient
Extended representation
Hyperglycemia True Concentration High Blood Glucose
Gastric polyposis True Number Many Stomach Polyp
(b) Variant of Ratio Abnormal statesProperty (P)
Property
Value (Vp) Attribute (A)
Attribute
Value (V) Object (O) Sub-Object (SO) Ratio
m/n (no unit) High m ratio True Ratio High The whole Focused m/n
Example Hyperglycemia True Concentration High blood glucose Glucose/Blood
m/n (focused on m of
same object)
High m ratio True Ratio High Object m m/n
Example High Albumin ratio True Concentration High Urine Albumin Albumin/Creatinine
m/n (focused on the ratio
of same object)
High m/n ratio True Ratio High Object m/n
Example Increased A/G ratio True Ratio High Blood A/G Albumin/Globulin
(a): Basic and extended representations (b): Representations of ratios.
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as the Object, and the polyps as the Sub-object [Table 1
(a), row 4].
Interoperability between properties and attributes
Our claim in this clause is the interoperability between
the abnormal states and data. Considering the interoper-
ability between the abnormal states and clinical test data,
the OP form itself may not be compatible with the
observational data.
A large amount of clinical test data is stored in hospitals.
To ensure the cross-compatibility between those data and
the abnormal states (described in EHR), the unified form
should be required for computer processing, so that an
exchange mechanism between the OP and OAV is
indispensable.
The OAV form can deal with both the quantitative and
qualitative representation of values. Most clinical test data
are quantitative, e.g., the arterial cross sectional area of
24 mm2 and can be represented by OAVqt as < artery (O),
cross sectional area (A), 24 mm2 (Vqt) > in our model.
Notably, the quantitative value can be converted to a
qualitative value such as “small (Vql),” with the threshold
given by each hospital.
In the case of an abnormal state “arterial stenosis,” we
can guarantee the interoperability between the quantita-
tive data and abnormal state by decomposing “stenosis”
into “cross sectional area is small”, which is represented
as < artery (O), cross sectional area (A), small (Vql) >.
Another example is the quantitative data “blood glucose
concentration level is 260 mg/dL”. It is represented by <
blood (O), glucose (SO), concentration (A), 260 mg/dL
(Vqt)>, and the interoperability between the quantitative
test data and the abnormal states “hyperglycemia” used inthe definition of diabetes is realized via qualitative repre-
sentation such as < blood (O), glucose (SO), concentration
(A), high (Vql) > in the extended OSoAV form.
Furthermore, another issue is the requirement of the
degree value of the property. Clinicians usually need to
transform test data into abnormal states in the case
report. Imagine a case where a highly elevated value is
observed in the clinical test. A simple OP <O, P, true >
does not satisfactorily capture such data, and thus the
degree of abnormal states may be needed. Therefore, we
introduce the Degree Value (Vd) like “severe”. Therefore,
we can describe such data in terms of the degree value
in the OPVd form < blood (O), hyperglycemia, severe
(Vd) > in a triplet like in the OAV form.
We recommend that the degree value should only
have minimum variations such as mild/moderate/severe
for representation because numerous degree values would
lead to dispersion and destruction of the unified represen-
tation. Taking the interoperability into account, it would
be considered preferable to decide how to set a threshold
for determining the degree value of “severe”. However, be-
cause such concrete threshold values tend to change with
time, such threshold values are left undetermined in this
study.
Here we introduce Property Value (Vp). A Property has
a meaning of < hyperglycemia, existence > or < hypergly-
cemia, true>. The value as “existence/nonexistence” or
“true/false” should be independent of the degree value.
However, because adding another form to the degree
value would make the system of representation forms
more complex, we deal with the degree value (e.g.,
mild/moderate/severe) as the specialization of the state
of hyperglycemia; we treat these values of “existence/
nonexistence” or “true/ false” in the same manner as
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both Vd and Vp.
The use of the value is e.g., a representation of the
condition of “not being hyperglycemia,” < hyperglycemia,
false>, in latent diabetes. For this reason, we consider
that the true/false value is needed for computer processing.
In conclusion, our model provided the following inter-
operable representation forms:
(1) The < OAV > form as clinical test data
(2) The < OPV > form as abnormal states and
(3) The extended form <OSoAV > as clinical test data
and < OSoPV > as abnormal states
Consequently, the OPV form is the same as the OAV
form. Therefore, the OPV can be compliant with the
unified representation (OAV triplet), which realizes the
interoperability between the data and abnormal states.Is-a Hierarchy of abnormality ontology
Ontologically, the structural abnormality, dysfunction,
pathological conditions, pathological processes, etc. are
kinds of abnormal states. We propose abnormality
ontology, which is a comprehensive ontology that covers
all of the abovementioned concepts, and abnormal states
are defined as the top level.
Clinicians work with strongly domain-specific know-
ledge, which causes difficulties in finding common and
generic knowledge across domains. A clear distinction be-
tween the basic/generic and specific concepts is required
to be made. To this end, we propose the following three
levels of abnormal states (Figure 1):
 Level 1: Generic abnormal states
 Level 2: Object-dependent abnormal states
 Level 3: Specific context-dependent abnormal statesLevel 1: generic abnormal states
Level 1 defines very basic (or generic) concepts, which
do not depend on any structural entity, i.e., object-
independent states. Examples include deformation, add-
itional/missing anatomical structures, translocation, and
dysfunction, which are commonly found in several objects,
and can be usable in several domains besides medicine,
such as machinery, materials, and aviation.
The top-level category of the generic abnormal states has
three subclasses: “structural abnormality,” “functional ab-
normality,” and “other abnormality” (Figure 2). A structural
abnormality is defined as an abnormal state associated with
structure. It has subcategories of material abnormality (e.g.,
degeneration), shape abnormality (e.g., deformation), size
abnormality, and conformational abnormality, such as
topological abnormality (e.g., translocation), or structuraldefects (e.g., additional/missing structures) etc., while still
retaining the identity of the structural body in question.
A functional abnormality is defined as an abnormal
state that is related to an impaired function and is classi-
fied into hyperfunction and malfunction. Malfunction is
subcategorized into dysfunction, function arrest, and
hypofunction.
Other abnormal states include parametric abnormal-
ities, which are classified into increased or decreased
parameters, depending on whether or not the attribute
has a higher or lower value than a threshold level.
Examples included increased/decreased pressure or
increased/decreased weight.
Our model has a recursive structure, in which the gen-
eric abnormal states at Level 1 are referred to by Level 2
object-dependent abnormal states.
Level 2: Object-dependent abnormal states
Level 2 defines object-dependent abnormal states. The
top level concepts at Level 2 are dependent on generic
structures, such as “wall-type structure,” “tubular struc-
ture,” and “bursiform structure,” which are common and
are used in several domains. Level 2 has been developed
by identifying the target object and specializing generic
abnormal states at Level 1 with consistency. For example,
by specializing “small in area” at Level 1, “narrowing tube,”
where the cross-sectional area has become narrow, is de-
fined at Level 2 this is further specialized in the definitions
“oil pipe narrowing” or “tracheal stenosis.”
In the lower layer of Level 2, abnormal states that are
dependent on medical domain-specific objects, such as
human anatomical structures, are defined and designed
to represent concepts at all required granularities in the
medical domain. Here in general, one problem arises in
how fine the level of granularity needs to be supported
in our ontology. In the case of “stenosis,” the term, “cor-
onary artery stenosis” in a specific organ (the coronary
artery) may be redundant. However, it is noteworthy that
the abnormal states in one anatomical object can influ-
ence the adjacent objects, which causes other abnormal
states. For example, although both are types of stenosis,
coronary artery stenosis is different from rhinostenosis
because the former causes myocardial ischemia and ische-
mic heart disease, whereas the latter causes sleep apnea.
Therefore, there is a need for distinct abnormal states at
specific organ levels.
From an ontological engineering point of view, our
framework for modeling abnormal states is intended to
capture the abnormal states from generic to specific
levels, so as to provide abnormal states at the required
granularity of specific organ/tissue/cell layers in the
medical domain.
Here, the abnormal states of a specific object defined
at Level 2 should be distinct from the disease-dependent
Figure 2 Top-level categories related to abnormal states. The
top level categories of abnormal states are classified into three
subclasses: “structural abnormality,” “functional abnormality,” and
“other abnormality such as parametric/nonparametric change and
so on”.
Figure 1 Three-level ontological model of abnormal states. This figure shows an example of the three levels of structural abnormality of our
abnormality ontology. “Level 1” defines generic concepts, which are object-independent states, e.g., “small in area.” “Level 2” defines object-dependent
abnormal states. States at the upper levels of Level 2 are dependent on generic structures, such as the “narrowing tube” and “narrowing valve,” which
are common and are used in several domains. Note that concepts at the lower level of the tree are specialized into medicine-specific concepts such
as vascular stenosis, arterial stenosis, and coronary artery stenosis. “Level 3” defines disease-dependent concepts. For example, “coronary artery stenosis
in angina pectoris” is defined as a constituent of the disease “angina pectoris” at Layer 3.
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in a context-independent manner at Level 2, and this is
referred to in Level 3 concepts in various diseases, such as
diabetes, metabolic syndrome, and lipodystrophy.
Currently, we are developing and enriching Level 2
concepts to link each Level 3 concept to the upper
common level concept.
Level 3: specific context-dependent abnormal states
Level 3 consists of context-dependent abnormal states,
which refer to the Level 2 abnormal states, and are spe-
cialized into specific disease-dependent ones. For example,
“rectal stenosis,” which is dependent on the rectum at
Level 2, is defined as a constituent of Crohn’s disease at
Level 3; this is also defined as a cause or an effect of other
diseases, such as rectal cancer, Hirschsprung disease, or
intestinal tuberculosis.
Application work
Causal chains of disease
We have been developing a disease ontology, in which a
disease is defined as a causal chain of abnormal states
[9]. We divided the diseases into two major kinds: (1)
ones where the etiological and pathological processes
are well understood and (2) otherwise. Case (2) includes
the so-called syndromes, typically represented in terms
of the criteria for diagnosis. Diseases of type (1) is identi-
fied by its inherent etiological/pathological process(es).
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careful examination of several diseases, we believe that
every disease of type (1) should have a cue for identifica-
tion. This means that we should be able to find the so-
called main pathological/etiological condition(s), which
theoretically characterize the disease to identify it. We
know that diseases of type (2) necessarily employ criteria
for diagnosis to identify the disease because of the lack of
knowledge regarding etiological/pathological processes.
In addition, we believe that we need a formulation for
organizing diseases in an is-a hierarchy in a disease model.
According to the definition of a disease, this would consist
of a causal chain(s), which consisted of nodes and links; a
disease would be represented as a directed acyclic graph
(DAG). We can introduce the is-a relation between dis-
eases using the inclusion relationship between the causal
chains as noted below.
Is-a relation between diseases Disease A is a super
class of disease B if all the causal chains at the class level
of disease A are included in those of disease B. The
inclusion of nodes (disorders) is judged by considering
the is-a relation between the nodes into account as well
as the sameness of the nodes.
Core causal chain of a disease Causal chain(s) of a
disease included in the chains of all its subclass diseases
is called the core causal chain of a disease.
Derived causal chains of a disease Causal chains of a
disease defined as possible causal chains of abnormal
states are called derived causal chains.
For example, <myocardial stenosis→myocardial ische-
mia > is the core causal chain for ischemic heart disease
and <myocardial stenosis→myocardial ischemia→myo-
cardial necrosis > is the core causal chain for myocardial
infarction. Here the core causal chain of Prinzmetal an-
gina is defined as < coronary spasm→…>, and if there are
some possible causes of spasm, e.g., smoking, it would be
added to the upstream of causal chains as < smoking
(nicotine absorption through the respiratory tract)→ cor-
onary spasm→… > as a derived causal chain (Figure 3).
Till date, clinicians have described the causal chains of
diseases and abnormal states. We have been using these
abnormal states to develop an is-a hierarchy of abnor-
malities. Abnormal states used in disease definitions in
the ontology are defined as abnormal states at Level 3,
where clinicians defined diseases in the respective med-
ical departments. We collected all causal relationships
from all disease concepts defined in the 13 medical
departments and combined the causal chains, including
the same abnormal states. As a result, the generic causal
chains that contain all causal relationships, including
approximately 21,000 abnormal states from 13 medicaldepartments have been generated [14]. For example, we
assume that a cardiovascular specialist in the division of
cardiovascular medicine describes “coronary artery sten-
osis” and its causal chain as < coronary artery stenosis→
myocardial ischemia→myocardial hypoxia > in ischemic
cardiac disease. This can be linked with “coronary artery
stenosis” in other diseases (e.g., hyperlipidemia) in other
departments (metabolic medicine). As a result, a generic
causal chain < accumulation of cholesterol→ coronary
artery stenosis→myocardial ischemia→myocardial hyp-
oxia > of hyperlipidemia can be obtained as a possible
causal relationship of abnormal states in the disease.
Discussion and related work
Discussion
We have introduced a unified form that represented an
abnormal state as a time-indexed “Property,” and decom-
posed it into its “Attribute” and “Value”. Furthermore, we
introduced the “Sub-Object,” which increases the flexibil-
ity with consistency. A property representation has several
advantages. First, it easily captures the essentials of each
disease because of its abstract nature. Second, it is rela-
tively insusceptible to a small parameter modification.
Third, it allows for the distinction between a definition of
a disease and a diagnostic task that requires a quantitative
representation.
Here, it should be noted that an abnormality can be
explained as some bodily feature that is not part of the
human life plan (unlike pregnancy) [15]; however, making
a decision about whether or not a particular state is “ab-
normal” is not the job of ontologists but medical experts,
who are required to make decisions on the basis of their
medical knowledge. For example, answering a question
about whether or not high HDL cholesterol level is an
“abnormal state” would not be a task for ontologists but
for medical experts; therefore, we do not discuss this issue
in the present study.
We demonstrated that our model is interoperable
between the quantitative and qualitative data found in
several medical records, and the conceptual knowledge
of the abnormal states in the definition of diseases.
In this study, we do not deal with the concrete value
that is to be set for the threshold because thresholds
may tend to change with time; for example, the cutoff
value of the fasting plasma glucose (FPG) level was revised
to 140 mg/dL in 1980 and to 126 in 1999 [16]. Therefore,
we can freely change the threshold, and to do so is
intrinsic. Nevertheless, even if the threshold changes,
hyperglycemia will remain as < blood, glucose concen-
tration, high >.
Diversity and heterogeneous representation problems
of abnormal states are solved by a unified and consistent
framework. However, in clinical DB, compound concepts
are often found in clinical terms. For example, “blood
Figure 3 Types of ischemic heart disease constituted of causal chains. This figure shows a couple of causal chain-constituted ischemic heart
disease. Each node shows the abnormal states, and each link indicates the causal relation between the abnormal states. A core causal chain of
each disease is colored differently: ischemic heart disease is orange, and the subclasses of the ischemic heart disease, myocardial infarction are
yellow. Prinzmetal angina is also a subclass of the ischemic heart disease consists of a pink core causal chain, and by an upstream extension
smoking is added in the derived causal chain. Organic angina pectoris is green and the accumulation of cholesterol is added to the derived
causal chain, which is a possible cause of arterial sclerosis.
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consists of two elements “blood” (Object) and “pressure”
(Attribute) joined for one meaning denoting an attribute.
Other examples are “WBC count” and “blood glucose
level”. Precisely speaking, these concepts should not be
dealt with as an ontological matter but as a variation of
data representation. Because medicine also requires an
exchange of the real world data such as clinical test data
between hospitals or institutions, in the next step, we will
deal with them as a variation of data representation.
We have developed an ontology of abnormal states
from generic to specific levels.
We have confirmed that abnormal states in the definition
of 10 major diseases from three medical departments can
be described with our description framework and suc-
ceeded in developing the is-a hierarchy from Level 1 to
Level 3 in our preliminary work.
Till date, ontological engineers have defined Level 1
concepts together with a major portion of the higher
levels of Level 2; clinicians have defined Level 3 concepts,
including 21,000 abnormal states in 6,000 diseases in
ontology. We plan to reformulate all the abnormal states
at Level 3 in terms of our framework and complete the
development of the middle concepts at Level 2 to link
both the upper Level 1 and Level 3 abnormal states.
Some readers might think Level 3 is unnecessary and
should be treated as the diagnostic instance level. How-
ever, by introducing Level 3 concepts, it will providecontextual information in the specific disease and contrib-
ute to the understanding of the background knowledge
related to the underlying mechanisms of pathological
process in the disease. Furthermore, Level 3 concepts are
important for finding commonalities between the various
diseases in terms of abnormal states. Therefore, we need
to develop disease context-dependent levels as Level 3.
Our ontology is able to distinguish the common con-
cepts from specific ones. Such an ontological approach
contributes to finding commonalities not only across
diseases in one division but also across departments. For
example, in cardiovascular medicine, “coronary artery
stenosis” in ischemic heart disease has a commonality
with “pulmonary artery stenosis” in the tetralogy of Fallot
in that they have the same upper abnormal state “arterial
stenosis”. In addition, it has a commonality with “cerebro-
vascular stenosis” in brain infarction in cerebral surgery in
that they both have the same upper abnormal state “vas-
cular stenosis”. A further commonality can be found with
“intestinal stenosis” in the ileus in gastroenterological
medicine in that they have the same generic structure-
dependent abnormal state “narrowing tube”. Therefore,
finding commonalities across medical departments could
offer a multidisciplinary perspective, allowing our method
to be applied to a wide range of research.
In our application work, we have captured all 21,000
abnormal states across the 13 medical departments with
both the is-a hierarchical structure of the abnormality
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different classes of abnormal states that are influenced
by each other. This allows us to integrate fragmented
knowledge of abnormal states, which might support the
application of various kinds of medical knowledge, as
follows.
(1) Conceptualization with little ambiguity
In the medical domain, there are quite a few ambigu-
ous clinical terms with the same name but different
meanings. One reason behind this is that clinicians use
each term in the context of specific diseases in their own
departments. For instance, the medical term “cardiac
hypertrophy” is used in both a division of cardiovascular
medicine and metabolic medicine. The definition of
hypertensive heart disease in cardiovascular medicine in-
dicates an increase in the thickness of the heart muscle,
which results from a pressure overload caused by hyper-
tension in the context of the heart. On the other hand, in
glycogenosis II (Pompe diseases) in metabolic medicine, it
implies a glycogen accumulation in the heart muscle,
which is caused by metabolic dysfunction (Figure 4). Be-
cause our model can provide the appropriate upper levels
of concepts and can give contextual information, it is
possible to clarify their difference.
Thus, our model can reveal the context of the mean-
ings that is usually hidden in the implicit backgroundFigure 4 Examples of hypertrophy constituted of causal chains. This f
hypertrophy is red. One usage is a constituent of a causal chain of the hyp
and the other is a constituent of a glycogenesis type II disease (Pompe dis
chain of each disease is yellow).knowledge of clinicians, and will contribute to making a
clear distinction between different types of concepts.
(2) Management of attributes by unified representation
If we allow clinicians to freely express the various attri-
butes/abnormalities, it would lead to a lack of consistency
and interoperability. Our model solves this problem by
providing a unified representation model of attributes/
abnormal states, as discussed in section Representation of
abnormal states, in which the attributes and properties are
differentiated; the properties are decomposed into < attri-
bute, attribute value>, as well as the advanced representa-
tion for ratios and meta-attributes.
(3) Quantitative assessment of commonality
Traditionally, abnormal states have been dealt with in
a manner specific to each disease in a particular medical
division. Here, our model enables the capture of abnormal
states common to several diseases, i.e., those that are at
the first two levels and those that are disease-independent,
which allows clinicians to overlook all abnormal states
across medical departments.
As a result, we can quantify and assess the degree of
commonality of abnormal states between different medical
departments. In addition, it is possible to verify the com-
monality of generic concepts by abstracting, or to findigure shows two different uses of cardiac hypertrophy. Each cardiac
ertensive heart disease in the cardiovascular department (upper figure),
ease) in the metabolic disease department shown below (A core causal
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any disease in other departments. For example, “esopha-
gostenosis,” which is a subclass of “narrowing tube,” may
demonstrate that it is specific to esophageal disease by
showing no commonality with other diseases, whereas
vascular stenosis can be confirmed as being more common
by showing a higher rate of commonality across multiple
diseases. Furthermore, our model may find commonalities
of abnormal states that have always been treated as quite
different abnormal states in different departments.
The clinicians’ treatment of the abnormal states in a
manner specific to a disease and/or particular clinical
division may have caused fragmentation of the same
concept into different ones that are treated as differ-
ently. Because our approach finds commonalities in the
organ-independent abnormal states, we can clean up
and deal with abnormal states more simply.
Thus, our ontology will provide a clue to revealing the
context embedded as background knowledge, which will
allow us to compare abnormal states and evaluate their
commonalities across medical departments.
Related work
Upper ontologies such as BFO [1,2], DOLCE [3], and
Galen [17] also deal with qualities and have contributed to
dealing with the semantics of data. BFO formalizes < Entity,
Property > (e.g., <rose, red>), whereas DOLCE uses < Entity,
Attribute, Value > formalization (e.g., <rose, color, red>),
and Galen adopts < Entity, Property, Value > formalization,
(e.g., <rose, redness, high>). Phenotypic Quality (PATO) [6]
is an ontology of phenotypic qualities, where the de-
scription was changed from < Entity, Attribute, Value > to
< Entity, Property (Quality) > (e.g., <eye, red>) when they
employed BFO. As explained in the Background section,
the YAMATO ontology is an upper ontology in Japan [4],
and offers interoperability among all of these descriptions,
allowing us to handle all three kinds of descriptions in our
representation model. Furthermore, PATO2YAMATO
provides the mapping of ontology terms of PATO to
YAMATO’s framework [5], and enables the interoper-
ability of the quality framework between the different
top-level ontologies such as BFO and DOLCE. In a prelim-
inary study, the application has succeeded in making the
connection between rat or mouse phenotype data, and re-
lated human abnormal states in the definition of diseases in
this study [18]. Because our extended model enables the
capture of commonalities of abnormal states across bio-
logical species, it may contribute to translational research
linking mouse experimental data and clinical research.
Furthermore, on the basis of the ontological approach,
if we make explicit the commonality and specificity of
abnormal states among multi-species, it should support
a comprehensive understanding of the basic common
mechanism or principles underlying organisms, and wouldlead to scientific discoveries by acquiring biomedical know-
ledge through an interdisciplinary approach across species.
In the medical domain, medical ontologies and stand-
ard vocabularies, such as ICD-10 [19], SNOMED-CT [20],
have been developed and extensively used in practice.
However, they are largely based on legacy system termin-
ologies, and thus have some ontological problems [21].
SNOMED-CT is a comprehensive terminology, which
contains more than 311,000 clinical terms. However, it
is not compliant with any formal upper level ontology.
SNOMED-CT allows for multiple inheritance that causes
a messy situation in the classification of entities, despite
the fact that partitioning implies sibling classes are
mutually disjoint, siblings at lower levels overlap each
other, which results in complex taxonomic graphs and
maintenance of the ontology difficult [20]. Furthermore,
SNOMED-CT does not distinguish disorders from dis-
eases. Not all disorders are diseases.
Our ontological proposal will help avoid such problems.
On the basis of YAMATO, we systematically define
abnormal states from the generic level (Level 1) to the
specific anatomical structure-dependent level (Level
2). Furthermore, by specializing Level 2 concepts into
a disease-context (disease-specific) level (Level 3), we
can distinguish abnormal states from diseases.
In our future plan, our ontology will be translated into
English and be mapped with SNOMED-CT clinical terms.
The mapping will evaluate the standard terminologies in
line with fundamental ontology engineering and provide
useful information about causal relationships of abnormal
states in the definition of each disease.
LOINC [8] provides the universal code names and
clinical terms by decomposing them. However, because
it focuses on the clinical observations, several of the
abnormal states appearing in the definition of diseases
are out of the scope for LOINC.
Although LOINC has < O (SO) A > like our model, it
does not have Value (V). For example, a test for glucose
tolerance about after 2 hours serum glucose for 100 g oral
is represented by “GLUCOSE^2H POST 100 G GLU-
COSE PO:MCNC:PT:SER/PLAS:QN”. The aim of LOINC
is to standardize the vocabulary for the representation of
clinical test data and is useful for interoperability among
various data. However, our claim is not isolated to adopt-
ing the OAV form. In order to realize the interoperability
between the clinical test data and abnormal states, a
Quantitative Value (Vqt) is needed in the representation
form. Our model can deal with quantitative data in the
OAV form; therefore, we can transform it into the OP
form of abnormal states. As a result, our model has an
ability to maintain the interoperability between the clinical
test data to abnormal states in diseases. Our model is not
merely a theoretical contribution. Only reutilizing the
existing resources cannot realize the interoperability
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more sophisticated organization of related representations
including quantitative and qualitative data to exploit all of
them in a consistent manner. To the best of our know-
ledge, our model is the first to make such an exploitation
possible, which will contribute to medical practices.
Our model contributes to the systematization of ab-
normal states on the basis of ontological theory, and is
able to distinguish between generic abnormal states,
object-dependent ones, and disease-specific ones with
unified representation. Moreover, the generic abnor-
mal states are referred to the lower level of abnormal
states by specializing them into the required granularity.
In the future, we plan to examine mappings to other data
sets of representations of clinical observations such as in
LOINC or MEDIS [22] that have been opened to the
public by The Medical Information System Development
Center in Japan (MEDIS-DC) for interoperability. These
mappings would provide a more comprehensive analysis
of interoperability between the clinical observation dataFigure 5 Computational representation of abnormal states from gene
states from “small in area” to “ischemic heart disease specific coronary arterand the conceptual knowledge of abnormal states in the
definition of diseases.
OGMS, which uses BFO as an upper-level ontology
[23], and DO [24] are both medical ontologies. However,
they do not have causal relationships between the abnor-
mal states in one disease. Our strategy will contribute to
providing a good resource for several medical researchers
to analyze the causes of diseases from the viewpoint of the
causal relationships of the abnormal states. Collaborative
efforts in OBO Foundry have tried to coordinate various
ontologies to support biomedical data integration [25]. In
the next step, we plan to convert our abnormal state
ontology into OBO format, and provide useful informa-
tion about the causal relationships in diseases.
In our practical application work, we published some
parts of the causal chain in disease ontology as Linked
Open Data (Disease Chain LOD) on the basis of our
RDF model [26]. It includes definitions of 2,103 diseases
and 13,910 abnormal states in six major medical depart-
ments extracted from the disease ontology on May 11,ric to specific level. This figure shows the specialization of abnormal
y stenosis” using HOZO.
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system for disease chains called the Disease Chain LOD
Viewer, which is available at http://lodc.med-ontology.jp/.
Furthermore, a browsing system of disease chains with
related information, which are obtained from other linked
data or web service from external datasets (e.g., ICD 10,
MeSH from DBPedia), is currently under development.
Conclusions
We proposed a representation model of abnormal states
designed in a unified manner. Our medical ontology
project was started seven years ago. Since then, it has been
refined and revised several times through discussion with
both ontologists and clinicians. Till date, we have applied
this model to approximately 21,000 abnormal states from
approximately 6000 diseases.
We have demonstrated that our model has interoper-
ability between quantitative and qualitative data and the
conceptual knowledge of abnormal states in the definition
of diseases. With this model, we have been developing an
ontology of abnormal states from generic to specific levels.Figure 6 A visual editing tool for causal chains to define disease conc
definition of disease concepts. It visualizes the causal chains defined in a seIn the application we considered, we built disease chains
consisting of causal relationships of abnormal states. By
combining the disease chains and the ontology, we have
captured all causal relations of the 21,000 abnormal states
in the 6,000 diseases across 13 medical departments.
Although abnormal states have traditionally been con-
sidered to be specific to each disease in a particular med-
ical department, our approach has found commonalities
among abnormal states across medical departments.
Methods
Data sources for representation and ontology
development of abnormal states
Medical doctors of The University of Tokyo Hospital
described the disease ontology, and definitions of dis-
eases were determined. Medical dictionaries [10,27] and
textbooks [28,29] were used as references. Using them
as resources, the definitions of the abnormal states in
the definition of diseases were decided through repeated
discussions by ontology engineers and medical experts.
The Level 1 generic concepts were based on YAMATOepts. This is a screenshot of our visual editing tool for editing the
lected disease as a directed graph like that in Figure 3.
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dependent concepts, have been generated by ontologists.
In our Japanese medical ontology project, anatomical
entities have been defined [30], and their anatomical
structure-dependent abnormal states have been defined by
the medical experts. Level 3 disease-specific abnormal
states were collected and generated by clinicians in 13
special fields.
Ontology editing tool
Ontology editing was performed using HOZO [31]. An
example of specialization of an abnormal state from a
generic level to a specific level is shown in Figure 5. The
generic abnormal state “Small in area” at Level 1 is defined
by < area (Attribute), small (Qualitative Value)>. Further-
more, at the top level concepts of Level 2, by identifying
the target object as “tubular structure,” and specializing
it into < cross-sectional area, small>,” we can define
“narrowing tube,” where the cross-sectional area of tube
became narrow. Lower concepts at Level 2 are specialized
to represent abnormal states specific to human anatomical
structures. For example, “vascular stenosis,” which is
dependent on “blood vessels,” is further specialized into
“coronary artery stenosis,” which is dependent on “coron-
ary artery.” Furthermore, “coronary artery stenosis” at
Level 2 is specialized into a disease-dependent one at
Level 3; for example, ischemic heart disease dependent. In
ischemic heart disease, coronary artery stenosis causes
“decreased blood flow,” which results in “myocardial
ischemia”.
Visual input/editing tool
We developed a visual editing tool, so that clinicians can
easily input and edit the definition of disease concepts.
Figure 6 shows its user interface. It enables us to visualize
the causal chains defined in a selected disease as a directed
graph. In the graph, nodes represent the abnormal states
and links represent causal relationships between them.
When users edit the graph, it automatically translates into
ontology according to the HOZO’s format. The ontology
can be exported in the OWL format by the export func-
tions of HOZO.
Although it has been implemented as a client applica-
tion using HOZO’s ontology API, we have published the
part of disease ontology as Linked Open Data with
SPARQL endpoint to get their causal chains [32]. The
Disease Chain LOD is available at the URL http://lodc.
med-ontology.jp/.
Endnotes
aOntologically, a state corresponds to a time-indexed prop-
erty. However, in the definition of diseases, time-indexed
abnormal states are rarely used (e.g., ischemia in the
definition of ischemic heart disease)” because the time-dependence of properties of diseases is out of the scope
of our project.
bIn this paper, although we mainly deal with a simple
parameter, additional parameters can be used when ne-
cessary. For example, in the definition of neonatal anemia,
we associate an additional attribute “age” and the value
“neonatal” with it.
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